Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1058-1063

  Pons, Roser ^a   Syrengelas, Dimitris ^b   Youroukos, Sotiris ^a   Orfanou, Irene ^a   Dinopoulos, Arqirios ^c   Cormand, Bru ^d   Ormazabal, Aida ^e   Garzía Cazorla, Angels ^e   Serrano, Mercedes ^e   Artuch, Rafael ^e  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Chorea; Dyskinesias; Levodopa; Tyrosine hydroxylase deficiency

Indexed keywords

AMANTADINE; CARBAMAZEPINE; ETIRACETAM; LEVODOPA; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; TYROSINE 3 MONOOXYGENASE; VALPROIC ACID; VIGABATRIN;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; ENZYME DEFICIENCY; FEVER; HUMAN; LEVODOPA INDUCED DYSKINESIA; MYOCLONUS SEIZURE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STRESS; STRIATONIGRAL DEGENERATION; TREATMENT DURATION; TREATMENT RESPONSE; TYROSINE HYDROXYLASE DEFICIENCY;

CHOREA; DYSKINESIAS; LEVODOPA; TYROSINE HYDROXYLASE DEFICIENCY;

CHILD; CHILD, PRESCHOOL; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; DYSTONIC DISORDERS; HUMANS; INFANT; LEVODOPA;

EID: 84881557335     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25382     Document Type: Article

References (15)

1. Pons R, The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. J Inherit Metab Dis 2009;32:321-332.
2. Hoffmann GF, Assmann B, Brautigam C, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 2003;54(suppl 6):S56-S65.
3. Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010;133(pt 6):1810-1822.
4. Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638.
5. Ormazabal A, Garcia-Cazorla A, Fernandez Y, Fernandez-Alvarez E, Campistol J, Artuch R. HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins. J Neurosci Methods 2005;142:153-158.
6. Pons R, Serrano M, Ormazabal A, et al. Tyrosine hydroxylase deficiency in three Greek patients with a common ancestral mutation. Mov Disord 2010;25:1086-1090.
7. Russel D, Rosenbaum P, Gowland C, et al. Gross Motor Function Measure Manual. 2nd ed. Hamilton, Ontario, Canada: McMaster University; 1993.
8. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
9. Cenci MA. L-dopa-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat Disord 2007;13(suppl 3):S263-S267.
10. Lee WT, Weng WC, Peng SF, Tzen KY. Neuroimaging findings in children with paediatric neurotransmitter diseases. J Inherit Metab Dis 2009;32:361-370.
11. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 2003;54(suppl 6):S32-S45.
12. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995;83:1197-1209.
13. Lin JP. The cerebral palsies: a physiological approach. J Neurol Neurosurg Psychiatry 2003;74(suppl 1):i23-i29.
14. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802.
15. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.